Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy

PURPOSE: Anti-programmed cell death protein 1 (PD1)±anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4) immune checkpoint inhibitors (ICIs) are standard therapeutic options for metastatic melanoma. We assessed whether biologic subtype according to primary tumor type or genomic subtype can funct...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Rose, April A N, Armstrong, Susan M, Hogg, David, Butler, Marcus O, Saibil, Samuel D, Arteaga, Diana P, Pimentel Muniz, Thiago, Kelly, Deirdre, Ghazarian, Danny, King, Ian, Kamil, Zaid Saeed, Ross, Kendra, Spreafico, Anna
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Immunotherapy Biomarkers
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7831745/
https://ncbi.nlm.nih.gov/pubmed/33483342
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001642
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados